TECTONIC THERAPEUTIC, INC. Other Executive Compensation Disclosures
Every other executive-compensation XBRL fact the company filed (policies, award timing, footnotes, adjustments), newest first. Long text is shortened; the filing has the full text.
- 2026-08-06: Disclosure Rule10b51Arr Adopted; Period 2026-04-01..2026-06-30; Value No.
- 2026-08-06: Disclosure Non Rule10b51Arr Adopted; Period 2026-04-01..2026-06-30; Value No.
- 2026-08-06: Disclosure Rule10b51Arr Terminated; Period 2026-04-01..2026-06-30; Value No.
- 2026-08-06: Disclosure Non Rule10b51Arr Terminated; Period 2026-04-01..2026-06-30; Value No.
| Filed | Disclosure | Qualifiers | Period | Value |
|---|---|---|---|---|
| 2026-08-06 10-Q | Rule10b51Arr Adopted | 2026-04-01..2026-06-30 | No | |
| 2026-08-06 10-Q | Non Rule10b51Arr Adopted | 2026-04-01..2026-06-30 | No | |
| 2026-08-06 10-Q | Rule10b51Arr Terminated | 2026-04-01..2026-06-30 | No | |
| 2026-08-06 10-Q | Non Rule10b51Arr Terminated | 2026-04-01..2026-06-30 | No | |
| 2026-05-07 10-Q | Rule10b51Arr Adopted | 2026-01-01..2026-03-31 | No | |
| 2026-05-07 10-Q | Non Rule10b51Arr Adopted | 2026-01-01..2026-03-31 | No | |
| 2026-05-07 10-Q | Rule10b51Arr Terminated | 2026-01-01..2026-03-31 | No | |
| 2026-05-07 10-Q | Non Rule10b51Arr Terminated | 2026-01-01..2026-03-31 | No | |
| 2026-04-24 DEF 14A | Insider Trading Policies Proc Adopted | 2025-01-01..2025-12-31 | Yes | |
| 2026-04-24 DEF 14A | Pay versus Performance Table | 2025-01-01..2025-12-31 | Pay Versus Performance The disclosure included in this section is prescribed by SEC rules and does not necessarily align with how the Company or the Compensation Committee view the link between the Company’s performance and Named Executive Officer pay. Required Tabular Disclosure of Pay Versus Perfo… | |
| 2026-04-24 DEF 14A | PEO Total Compensation | Individual: ErikOstrowski | 2024-01-01..2024-12-31 | $1.09M |
| 2026-04-24 DEF 14A | PEO Total Compensation | Individual: AliseReicin | 2024-01-01..2024-12-31 | $5.90M |
| 2026-04-24 DEF 14A | PEO Actually Paid Compensation | Individual: ErikOstrowski | 2024-01-01..2024-12-31 | $956.46K |
| 2026-04-24 DEF 14A | PEO Actually Paid Compensation | Individual: AliseReicin | 2024-01-01..2024-12-31 | $16.25M |
| 2026-04-24 DEF 14A | Named Executive Officers Footnote | 2025-01-01..2025-12-31 | (1) The following individuals are our PEO and other non-PEO Named Executive Officers for each fiscal year: Year First PEO Second PEO Non-PEO Named Executive Officers 2025 — Alise Reicin, M.D. Daniel Lochner and Marcella K. Ruddy, M.D. 2024 Erik Ostrowski (through June 20, 2024) Alise Reicin, M.D. (s… | |
| 2026-04-24 DEF 14A | PEO Name | Individual: AliseReicin | 2025-01-01..2025-12-31 | Alise Reicin |
| 2026-04-24 DEF 14A | PEO Name | Individual: ErikOstrowski | 2024-01-01..2024-06-19 | Erik Ostrowski |
| 2026-04-24 DEF 14A | PEO Name | Individual: AliseReicin | 2024-06-20..2024-12-31 | Alise Reicin |
| 2026-04-24 DEF 14A | PEO Name | Individual: ErikOstrowski | 2023-01-01..2023-12-31 | Erik Ostrowski |
| 2026-04-24 DEF 14A | Adjustment To PEO Compensation Footnote | 2025-01-01..2025-12-31 | (3) Represents the amount of CAP to our PEOs and the average amount of CAP to our Non-PEO Named Executive Officers, respectively, as computed in accordance with Item 402(v) of Regulation S-K. The dollar amounts do not reflect the actual amount of compensation earned by or paid to our Named Executive… | |
| 2026-04-24 DEF 14A | Adjustment To Non PEO NEO Compensation Footnote | 2025-01-01..2025-12-31 | (3) Represents the amount of CAP to our PEOs and the average amount of CAP to our Non-PEO Named Executive Officers, respectively, as computed in accordance with Item 402(v) of Regulation S-K. The dollar amounts do not reflect the actual amount of compensation earned by or paid to our Named Executive… | |
| 2026-04-24 DEF 14A | Adjustment To Compensation | AdjToComp: EqtyAwrdsInSummryCompstnTblForAplblYr; ExecutiveCategory: Peo; Individual: AliseReicin | 2025-01-01..2025-12-31 | -$6.32M |
| 2026-04-24 DEF 14A | Adjustment To Compensation | AdjToComp: YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstd; ExecutiveCategory: Peo; Individual: AliseReicin | 2025-01-01..2025-12-31 | $2.84M |
| 2026-04-24 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrs; ExecutiveCategory: Peo; Individual: AliseReicin | 2025-01-01..2025-12-31 | -$5.33M |
| 2026-04-24 DEF 14A | Adjustment To Compensation | AdjToComp: VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYr; ExecutiveCategory: Peo; Individual: AliseReicin | 2025-01-01..2025-12-31 | $366.40K |
| 2026-04-24 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYr; ExecutiveCategory: Peo; Individual: AliseReicin | 2025-01-01..2025-12-31 | -$3.32M |
| 2026-04-24 DEF 14A | Adjustment To Compensation | AdjToComp: FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYr; ExecutiveCategory: Peo; Individual: AliseReicin | 2025-01-01..2025-12-31 | $0.00 |
| 2026-04-24 DEF 14A | Adjustment To Compensation | AdjToComp: EqtyAwrdsInSummryCompstnTblForAplblYr; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | -$2.36M |
| 2026-04-24 DEF 14A | Adjustment To Compensation | AdjToComp: YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstd; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | $1.08M |
| 2026-04-24 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrs; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | -$1.89M |
| 2026-04-24 DEF 14A | Adjustment To Compensation | AdjToComp: VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYr; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | $118.76K |
| 2026-04-24 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYr; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | -$1.16M |
| 2026-04-24 DEF 14A | Adjustment To Compensation | AdjToComp: FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYr; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | $0.00 |
| 2026-04-24 DEF 14A | Equity Valuation Assumption Difference Footnote | 2025-01-01..2025-12-31 | The valuation assumptions used to calculate fair values did not materially differ from those disclosed at the time of grant. | |
| 2026-04-24 DEF 14A | Compensation Actually Paid Vs Net Income | 2025-01-01..2025-12-31 | CAP and Net Loss The chart below shows the relationship between the compensation actually paid to our PEOs and the average compensation actually paid to our non-PEO Named Executive Officers, on the one hand, to the Company’s Net Loss over the three years presented in the table, on the other. | |
| 2026-04-24 DEF 14A | Compensation Actually Paid Vs Total Shareholder Return | 2025-01-01..2025-12-31 | CAP and Cumulative TSR The chart below shows the relationship between the CAP to our PEOs and the average CAP to our non-PEO Named Executive Officers, on the one hand, to the Company’s cumulative TSR over the three years presented in the table, on the other. | |
| 2026-04-24 DEF 14A | Award Timing MNPI Disclosure | 2025-01-01..2025-12-31 | Policies and Practices Related to the Grant of Certain Equity Awards Close in Time to the Release of Material Nonpublic Information From time to time, the Company grants stock options to its employees, including the Named Executive Officers. Beginning in fiscal year 2025, the Company grants annual r… | |
| 2026-04-24 DEF 14A | Award Timing Predetermined | 2025-01-01..2025-12-31 | Yes | |
| 2026-04-24 DEF 14A | Award Timing MNPI Considered | 2025-01-01..2025-12-31 | Yes | |
| 2026-04-24 DEF 14A | Award Timing How MNPI Considered | 2025-01-01..2025-12-31 | The Compensation Committee considers whether there is any material nonpublic information (“MNPI”) about the Company when determining the timing of stock option grants and does not seek to time the award of stock options in relation to the Company’s public disclosure of MNPI. | |
| 2026-04-24 DEF 14A | MNPI Disclosure Timed For Compensation Val | 2025-01-01..2025-12-31 | No | |
| 2026-02-26 10-K | Material Terms Of Trading Arrangement | 2025-10-01..2025-12-31 | Item 9B. Other Information. During the three months ended December 31, 2025, the following directors of the Company adopted a “Rule 10b5-1 trading arrangement” as the term is defined in Item 408(a) of Regulation S-K, all of which were entered into during an open trading window in accordance with the… | |
| 2026-02-26 10-K | Rule10b51Arr Adopted | 2025-10-01..2025-12-31 | No | |
| 2026-02-26 10-K | Non Rule10b51Arr Adopted | 2025-10-01..2025-12-31 | No | |
| 2026-02-26 10-K | Rule10b51Arr Terminated | 2025-10-01..2025-12-31 | No | |
| 2026-02-26 10-K | Non Rule10b51Arr Terminated | 2025-10-01..2025-12-31 | No |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |